文献速递系统性红斑狼疮

BICLA应答在SLE临床实践中的意义:两项III期试验事后分析

What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
PubMed 文献 · Arthritis Rheumatol · 2021-09-22

该事后分析汇总TULIP-1和TULIP-2两项III期试验数据,比较BICLA应答者与非应答者在临床评估、患者报告结局和医疗资源利用方面的差异。结果显示BICLA应答者 flares 率更低、激素减量达标率更高、PROs改善更显著、SLE相关住院/急诊更少,支持BICLA作为与患者 care 相关指标关联的试验终点。

要点

  • BICLA应答者较非应答者 flares 率更低、持续口服激素减至≤7.5 mg/天比例更高。
  • BICLA应答者PROs(FACIT-F、SF-36)改善更显著,SLE相关住院/急诊更少。
  • BICLA应答与全局及器官特异性疾病活动度改善相关,狼疮相关严重不良事件更少。

核心结论

  • BICLA应答与SLE临床评估、患者报告结局及医疗资源利用方面的临床获益相关,支持其作为与患者 care 重要指标关联的临床试验终点。

研究设计与样本

  • 为III期随机安慰剂对照52周TULIP-1(NCT02446912;n=457)和TULIP-2(NCT02446899;n=362)试验的事后汇总分析,评估静脉anifrolumab(150/300 mg每4周一次)治疗中重度SLE患者。
  • 比较BICLA应答者与非应答者从基线至第52周在临床评估、PROs和医疗资源使用方面的变化,不考虑治疗分组。

主要发现

  • BICLA应答者(n=318)较非应答者(n=501) flares 率更低、持续口服糖皮质激素减至≤7.5 mg/天比例更高、PROs(FACIT-F、SF-36)改善更大、SLE相关住院/急诊就诊更少(均名义P<0.001)。
  • BICLA应答者较非应答者全局及器官特异性疾病活动度改善更大(PGA、SLEDAI-2K、CLASI活动度、关节计数;均名义P<0.001)。
  • BICLA应答者狼疮相关严重不良事件少于非应答者。

关键数值与推荐

  • BICLA应答者(n=318)与非应答者(n=501)比较, flares 率更低(名义P<0.001)。
  • BICLA应答者持续口服糖皮质激素减至≤7.5 mg/天比例更高(名义P<0.001)。
  • BICLA应答者SLE相关住院/急诊就诊更少(名义P<0.001)。
  • BICLA应答者PGA、SLEDAI-2K、CLASI活动度及关节计数改善更大(均名义P<0.001)。

临床怎么用

  • BICLA应答可作为临床实践中反映 flares、激素减量、PROs及医疗资源利用综合获益的指标。
  • 评估SLE治疗应答时,BICLA应答与患者重要的临床结局和资源使用相关,支持其在实践中的相关性。

局限性

  • 为事后分析,结果需谨慎解读。
  • 分析不考虑治疗分组,可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) is a validated global measure of treatment response in systemic lupus erythematosus (SLE) clinical trials. To understand the relevance of BICLA in clinical practice, we investigated relationships between BICLA response and routine SLE assessments, patient-reported outcomes (PROs), and medical resource utilization. METHODS: This was a post hoc analysis of pooled data from the phase III, randomized, placebo-controlled, 52-week TULIP-1 (ClinicalTrials.gov identifier: NCT02446912; n = 457) and TULIP-2 (ClinicalTrials.gov identifier: NCT02446899; n = 362) trials of intravenous anifrolumab (150/300 mg once every 4 weeks) in patients with moderate-to-severe SLE. Changes from baseline to week 52 in clinical assessments, PROs, and medical resource use were compared in BICLA responders versus nonresponders, regardless of treatment assignment. RESULTS: BICLA responders (n = 318) achieved significantly improved outcomes compared with nonresponders (n = 501), including lower flare rates, higher rates of attainment of sustained oral glucocorticoid taper to ≤7.5 mg/day, greater improvements in PROs (Functional Assessment of Chronic Illness Therapy-Fatigue, Short Form 36 Health Survey), and fewer SLE-related hospitalizations/emergency department visits (all nominal P < 0.001). Compared with nonresponders, BICLA responders had greater improvements in global and organ-specific disease activity (Physician's Global Assessment, SLE Disease Activity Index 2000, Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity, and joint counts; all nominal P < 0.001). BICLA responders had fewer lupus-related serious adverse events than nonresponders. CONCLUSION: BICLA response is associated with clinical benefit in SLE assessments, PROs, and medical resource utilization, confirming its value as a clinical trial end point that is associated with measures important to patient care.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Furie R, Morand EF, Bruce IN, et al. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Arthritis Rheumatol. 2021. PMID: 33913260. doi:10.1002/art.41778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。